Negative regulators of cardiac hypertrophy

被引:106
作者
Hardt, SE
Sadoshima, J
机构
[1] UMDNJ, Cardiovasc Res Inst, Dept Cell Biol & Mol Med, Newark, NJ 07103 USA
[2] Heidelberg Univ, Dept Cardiol, Heidelberg, Germany
关键词
hypertrophy; signal transduction; negative regulation;
D O I
10.1016/j.cardiores.2004.03.015
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Throughout the past decade, much effort has been spent on deciphering the signaling pathways positively mediating cardiac hypertrophy. Recently, several endogenous molecules in the heart have been shown to negatively regulate cardiac hypertrophy. One group of these molecules is constitutively active at baseline, while molecules belonging to the second group serve as negative feedback regulators, which are activated in response to pathologic insults. Studies upon the negative regulators of cardiac hypertrophy may allow us to develop novel strategies to treat heart failure by mimicking the naturally preferred mechanisms to maintain homeostasis. In addition, the search for molecular targets of these negative regulators may allow us to identify novel positive mediators of hypertrophy. The aim of this article is to provide a brief overview of these newly identified negative regulators of cardiac hypertrophy. (C) 2004 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:500 / 509
页数:10
相关论文
共 113 条
  • [1] beta-catenin is a target for the ubiquitin-proteasome pathway
    Aberle, H
    Bauer, A
    Stappert, J
    Kispert, A
    Kemler, R
    [J]. EMBO JOURNAL, 1997, 16 (13) : 3797 - 3804
  • [2] Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation
    Alt, JR
    Cleveland, JL
    Hannink, M
    Diehl, JA
    [J]. GENES & DEVELOPMENT, 2000, 14 (24) : 3102 - 3114
  • [3] ANTOS CL, 2002, P NATL ACAD SCI USA, V8, P8
  • [4] Protection against reperfusion-induced arrhythmias by human thioredoxin
    Aota, M
    Matsuda, K
    Isowa, N
    Wada, H
    Yodoi, JJ
    Ban, T
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1996, 27 (05) : 727 - 732
  • [5] Transgenic overexpression of caveolin-3 in the heart induces a cardiomyopathic phenotype
    Aravamudan, B
    Volonte, D
    Ramani, R
    Gursoy, E
    Lisanti, MP
    London, B
    Galbiati, F
    [J]. HUMAN MOLECULAR GENETICS, 2003, 12 (21) : 2777 - 2788
  • [6] Peroxisome proliferator-activated receptor γ plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo
    Asakawa, M
    Takano, H
    Nagai, T
    Uozumi, H
    Hasegawa, H
    Kubota, N
    Saito, T
    Masuda, Y
    Kadowaki, T
    Komuro, I
    [J]. CIRCULATION, 2002, 105 (10) : 1240 - 1246
  • [7] Fas receptor signaling inhibits glycogen synthase kinase 3β and induces cardiac hypertrophy following pressure overload
    Badorff, C
    Ruetten, H
    Mueller, S
    Stahmer, M
    Gehring, D
    Jung, F
    Ihling, C
    Zeiher, AM
    Dimmeler, S
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2002, 109 (03) : 373 - 381
  • [8] Deactivation of peroxisome proliferator-activated receptor-α during cardiac hypertrophic growth
    Barger, PM
    Brandt, JM
    Leone, TC
    Weinheimer, CJ
    Kelly, DP
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (12) : 1723 - 1730
  • [9] Melusin, a muscle-specific integrin β1-interacting protein, is required to prevent cardiac failure in response to chronic pressure overload
    Brancaccio, M
    Fratta, L
    Notte, A
    Hirsch, E
    Poulet, R
    Guazzone, S
    De Acetis, M
    Vecchione, C
    Marino, G
    Altruda, F
    Silengo, L
    Tarone, G
    Lembo, G
    [J]. NATURE MEDICINE, 2003, 9 (01) : 68 - 75
  • [10] The dual-specificity phosphatase MKP-1 limits the cardiac hypertrophic response in vitro and in vivo
    Bueno, OF
    De Windt, LJ
    Lim, HW
    Tymitz, KM
    Witt, SA
    Kimball, TR
    Molkentin, JD
    [J]. CIRCULATION RESEARCH, 2001, 88 (01) : 88 - 96